SAB Biotherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	41	36	25	340	-	-
Market Cap Growth	-	41.70%	-92.52%	-	-	-
Enterprise Value	-10	-15	16	309	-4	1
PE Ratio	-0.85	-0.85	-1.35	-19.80	-	-
PS Ratio	17.96	16.07	1.06	5.58	-	-
PB Ratio	0.70	0.63	0.82	8.81	-	-
P/FCF Ratio	-1.42	-1.42	-0.99	-37.91	-	-
P/OCF Ratio	-1.43	-1.43	-1.08	170.89	-	-
EV/Sales Ratio	-6.56	-6.56	0.68	5.07	-0.08	0.38
EV/EBITDA Ratio	0.39	0.39	-1.08	-20.30	-0.21	-0.16
EV/EBIT Ratio	0.35	0.35	-0.88	-18.31	-0.22	-0.15
EV/FCF Ratio	0.58	0.58	-0.64	-34.44	1.65	-0.13
Debt / Equity Ratio	0.10	0.10	0.19	0.22	0.21	-3.31
Debt / EBITDA Ratio	-0.15	-0.15	-0.39	-0.56	0.38	-0.93
Debt / FCF Ratio	-0.23	-0.23	-0.23	-0.95	-2.99	-0.78
Quick Ratio	5.23	5.23	1.37	1.80	3.00	1.98
Current Ratio	5.45	5.45	1.47	1.90	3.12	2.01
Asset Turnover	0.05	0.05	0.42	0.88	1.48	-
Interest Coverage	-132.83	-132.83	-61.06	-57.22	43.88	-19.97
Return on Equity (ROE)	-144.70%	-144.70%	-53.50%	-44.20%	109.60%	-
Return on Assets (ROA)	-88.60%	-88.60%	-32.60%	-24.90%	54.00%	-
Return on Capital (ROIC)	-60.24%	-60.24%	-78.18%	-28.46%	43.61%	-162.67%
Earnings Yield	-104.90%	-117.30%	-73.83%	-5.05%	-	-
FCF Yield	-62.83%	-70.26%	-100.65%	-2.64%	-	-
Buyback Yield / Dilution	-26.86%	-26.86%	-59.20%	-1.21%	23.30%	-
Total Shareholder Return	-26.86%	-26.86%	-59.20%	-1.21%	23.30%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).